The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot Study
1 other identifier
interventional
15
1 country
1
Brief Summary
Gastroesophageal reflux disease related symptoms are reported by 10-20% of the adult population and of those 50-75% report symptoms during sleep time. The prevalence of nocturnal GERD (nGERD) is estimated to be about 25% in general population. nGERD causes sleep fragmentation, difficulty falling asleep, daytime sleepiness, reduced work productivity and decreased quality of life. Additionally, nighttime gastroesophageal reflux has been associated with increased risk of GERD-related complications such as severe erosive esophagitis, peptic stricture, esophageal ulcer, Barrett's esophagus, and esophageal adenocarcinoma. Furthermore, nocturnal gastroesophageal reflux has been noted to be associated with atypical and extra-esophageal manifestations as well as sleep disturbances. Overall, patients with nocturnal gastroesophageal reflux are more likely to develop a more severe form of GERD. The mainstay of treatment of nighttime gastroesophageal reflux is a proton pump inhibitor (PPI). However, nighttime heartburn is the most common breakthrough symptom in patients with GERD, who failed PPI treatment. Other important therapies for nighttime GERD include, lifestyle modifications, such as elevating the head of the bed, avoiding eating at least three hours before bedtime, maintaining appropriate sleep hygiene and avoiding the right decubitus position. Elevating the upper torso by raising the head of the bed and avoiding the right-lateral decubitus position have been shown to improve nocturnal symptoms. Several studies have shown that sleeping in the left decubitus position decrease esophageal acid exposure by reducing 13-76% of the reflux episodes. Studies have shown that the right decubitus position increases the rate of transient lower esophageal sphincter relaxations (TLESRs) accompanied by acid reflux, as compared with the left recumbent position. Moreover, maintaining the left lateral recumbent position, reduced by 87% esophageal acid exposure and nocturnal symptoms. LEFT is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland. This technology is designed to train patients to sleep on their left side by a gentle vibration signal once it detects that they are sleeping on their back or right side. Thus, this technique may reduce gastroesophageal reflux and thus provides relief of heartburn and regurgitation during sleep time. The purpose of this study is to determine the usefulness of positional therapy, using the LEFT device, as a nonmedical tool to control GERD-related nocturnal symptoms.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Mar 2021
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 10, 2020
CompletedFirst Posted
Study publicly available on registry
August 5, 2020
CompletedStudy Start
First participant enrolled
March 4, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 21, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
May 21, 2024
CompletedJune 28, 2023
June 1, 2023
2.2 years
July 10, 2020
June 26, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary outcome of the study is to determine if positional therapy, using the LEFT device, is effective in improving nighttime GERD-related symptoms as measured by GERD symptoms checklist (questionnaire, involves no specific units of measure).
Patients will undergo positional therapy using the LEFT device for a period of one month
1 month
Secondary Outcomes (1)
The secondary outcome of the study is to determine if positional therapy improves quality of sleep and health-related quality of life as measured by Epworth Sleepiness, Scale and Sleep quality, SF-36 and Berlin questionnaires. No units of measure.
1 month
Study Arms (1)
LEFT Device Arm
EXPERIMENTALSubjects in this arm will wear the LEFT device for 1 month
Interventions
LEFT device is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland.
Eligibility Criteria
You may qualify if:
- Patients over the age of 18 who have proven GERD (with nighttime heartburn at least 3 days a week).
- Agree to undergo sleep positioning therapy.
- Able to read, understand, and complete study questionnaires.
- Have mobile phones with an operating system (Android or iOS) that supports the LEFT device.
You may not qualify if:
- \. Patients who are under the age of 18.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Metrohealth Medical Center
Cleveland, Ohio, 44109, United States
Related Publications (17)
Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56. doi: 10.1016/s0016-5085(97)70025-8.
PMID: 9136821BACKGROUNDFass R, Quan SF, O'Connor GT, Ervin A, Iber C. Predictors of heartburn during sleep in a large prospective cohort study. Chest. 2005 May;127(5):1658-66. doi: 10.1378/chest.127.5.1658.
PMID: 15888843BACKGROUNDFass R. Effect of gastroesophageal reflux disease on sleep. J Gastroenterol Hepatol. 2010 May;25 Suppl 1:S41-4. doi: 10.1111/j.1440-1746.2009.06210.x.
PMID: 20586864BACKGROUNDLagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825-31. doi: 10.1056/NEJM199903183401101.
PMID: 10080844BACKGROUNDElleuch N, Hefaiedh R, Karoui S, Fekih M, Zouiten L, Matri S, Filali A. [Nocturnal gastroesophageal reflux. About a pH metric series]. Tunis Med. 2015 Apr;93(4):223-7. French.
PMID: 26375738BACKGROUNDChey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M. Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin. 2009 Aug;25(8):1869-78. doi: 10.1185/03007990903035745.
PMID: 19530980BACKGROUNDHarvey RF, Gordon PC, Hadley N, Long DE, Gill TR, Macpherson RI, Beats BC, Tottle AJ. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987 Nov 21;2(8569):1200-3. doi: 10.1016/s0140-6736(87)91332-8.
PMID: 2890820BACKGROUNDHamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988 May;33(5):518-22. doi: 10.1007/BF01798350.
PMID: 3359906BACKGROUNDJohnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci. 1981 Aug;26(8):673-80. doi: 10.1007/BF01316854.
PMID: 7261830BACKGROUNDKhan BA, Sodhi JS, Zargar SA, Javid G, Yattoo GN, Shah A, Gulzar GM, Khan MA. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J Gastroenterol Hepatol. 2012 Jun;27(6):1078-82. doi: 10.1111/j.1440-1746.2011.06968.x.
PMID: 22098332BACKGROUNDStanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion. 1977 Feb;15(2):104-9. doi: 10.1159/000197991.
PMID: 14044BACKGROUNDKhoury RM, Camacho-Lobato L, Katz PO, Mohiuddin MA, Castell DO. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1999 Aug;94(8):2069-73. doi: 10.1111/j.1572-0241.1999.01279.x.
PMID: 10445529BACKGROUNDKatz LC, Just R, Castell DO. Body position affects recumbent postprandial reflux. J Clin Gastroenterol. 1994 Jun;18(4):280-3. doi: 10.1097/00004836-199406000-00004.
PMID: 8071510BACKGROUNDShay SS, Conwell DL, Mehindru V, Hertz B. The effect of posture on gastroesophageal reflux event frequency and composition during fasting. Am J Gastroenterol. 1996 Jan;91(1):54-60.
PMID: 8561144BACKGROUNDvan Herwaarden MA, Katzka DA, Smout AJ, Samsom M, Gideon M, Castell DO. Effect of different recumbent positions on postprandial gastroesophageal reflux in normal subjects. Am J Gastroenterol. 2000 Oct;95(10):2731-6. doi: 10.1111/j.1572-0241.2000.03180.x.
PMID: 11051341BACKGROUNDPerson E, Rife C, Freeman J, Clark A, Castell DO. A Novel Sleep Positioning Device Reduces Gastroesophageal Reflux: A Randomized Controlled Trial. J Clin Gastroenterol. 2015 Sep;49(8):655-9. doi: 10.1097/MCG.0000000000000359.
PMID: 26053170BACKGROUNDAllampati S, Lopez R, Thota PN, Ray M, Birgisson S, Gabbard SL. Use of a positional therapy device significantly improves nocturnal gastroesophageal reflux symptoms. Dis Esophagus. 2017 Feb 1;30(3):1-7. doi: 10.1111/dote.12495.
PMID: 27629558BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ronnie Fass, MD
Director, Division of Gastroenterology and Hepatology at Metrohealth MC
- PRINCIPAL INVESTIGATOR
Abdulfatah Issak, MD
Gastroenterology Fellow at Metrohealth MC
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Ronnie Fass, MD, FACG, Director, Division of Gastroenterology and Hepatology, Head, Esophageal and Swallowing Center
Study Record Dates
First Submitted
July 10, 2020
First Posted
August 5, 2020
Study Start
March 4, 2021
Primary Completion
May 21, 2023
Study Completion
May 21, 2024
Last Updated
June 28, 2023
Record last verified: 2023-06